FY23 Corporate Strategy and Sustainability Journey

FY23 Highlights (1/2) 1 Healthy business growth o Revenues in North America Generics & in Branded markets of India & EM crossed $ 1 bn mark for second consecutive year 2 Launched Lenalidomide capsules in the US (as part of the volume limited settlement with innovator) 3 Healthy EBITDA at 30% and ROCE at 35% 4 Strong Free Cash Flows, leading to a net cash surplus of $ 614 mn 5 Acquisitions of - o Cardiovascular brand CidmusⓇ in India ○ Mayne Pharma's US generic product portfolio ○ Eton's branded and generic injectable products in the US 6 Enhanced focus on core by divesting certain non-core brands in India

View entire presentation